Clinical and metabolic effects of rosiglitazone and metformin in non-obese women with polycystic ovary syndrome and metabolic disorders: a randomized controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13003529

Enrollment

Unknown

Registered

2013-08-17

Start date

2013-10-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovary syndrome

Interventions

B:rosiglitazone 4mg, qd, 6months

A:metformin (500mg, tid, 6months)

Eligibility

Sex/Gender

Female

Age

15 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Women diagnosed of PCOS; 2. BMI=20uu/ml or HOMA-IR>2.77

Exclusion criteria

Exclusion criteria: 1. Women who are pregnant; 2. Women who have specified coexisting disease affecting the glycometabolism and lipid metabolism; 3. Women who receive hormonal therapy in the last three months; 4. Heavy smokers(>10 cigarettes/day); 5. BMI<18 kg/m^2.

Design outcomes

Primary

Measure	Time frame
HOMA-I;	—

Secondary

Measure	Time frame
blood lipids;Obesity related indexes;hyperandrogenic clinical manifestation;sex hormon;	—

Countries

China

Contacts

Public ContactWei HUANG

1343174200@qq.com+86 28 85501346

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026